Search

Your search keyword '"Rizqi Amanda Nabilah"' showing total 3 results
Start Over Author "Rizqi Amanda Nabilah"
3 results on '"Rizqi Amanda Nabilah"'

1. The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study

Author

Rakhmad Hidayat, Rizqi Amanda Nabilah, Marc Fisher, Tiara Aninditha, Mohammad Kurniawan, Riwanti Estiasari, Luh Ari Indrawati, Ahmad Yanuar Safri, Taufik Mesiano, Al Rasyid, and Salim Harris

Subjects
ABCB1, Clopidogrel, Response variability, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Background Clopidogrel has been the primary choice of antiplatelet in ischemic stroke that inhibits adenosine diphosphate (ADP)-induced platelet aggregation. P-glycoprotein (P-gp) multidrug resistance-1 (MDR1) is a transmembrane efflux transporter in intestinal cells that plays a significant role in clopidogrel absorption, therefore may affect platelet aggregation. P-gp is encoded by the ABCB1 gene. This study aims to evaluate the effect of ABCB1 polymorphism on clopidogrel response variability in ischemic stroke patients and its genotype frequency. Methods A cross-sectional study was conducted in ischemic stroke patients who received clopidogrel between 2020 and 2023 in RSUI/RSCM. All subjects were assessed for ABCB1 polymorphisms C3435T and C1236T. Platelet aggregation were measured using VerifyNow PRU. Clopidogrel response variability was classified into unresponsive (> 208 PRU), responsive (95–208 PRU), and bleeding risk (

Published
2024
Full Text
View/download PDF

2. Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia

Author

Rakhmad Hidayat, Rizqi Amanda Nabilah, Al Rasyid, Salim Harris, Alida R. Harahap, Herqutanto Herqutanto, Melva Louisa, Erlin Listyaningsih, Aldy Safruddin Rambe, and Tonny Loho

Subjects
Male, Stroke, Cross-Sectional Studies, Ticlopidine, Treatment Outcome, Indonesia, Risk Factors, Humans, Drug Therapy, Combination, General Medicine, Platelet Aggregation Inhibitors, Clopidogrel, Ischemic Stroke
Abstract

Objective. Clopidogrel is a common antiplatelet used as secondary prevention of ischemic stroke, known to have better efficacy than aspirin, with a equivalent safety profile. However, clopidogrel resistance is not uncommon but has not been widely studied in Asia. This study will further assess clopidogrel resistance and its risk factors.Materials and Methods. A cross-sectional study was conducted at Rumah Sakit Universitas, Indonesia, and Rumah Sakit Cipto Mangunkusumo, Indonesia in 2020-2021. All patients had had at least one episode of ischemic stroke. Clopidogrel resistance was assessed using a VerifyNow assay.Results. 57 subjects were enrolled in this study. We found 15.8% of subjects were clopidogrel resistant. Gender was significantly associated with clopidogrel resistance, with males having 80% lower clopidogrel resistance (OR 0.2 (95% CI 0.022 – 0.638); P=0.006). Meanwhile, smoking was not associated with clopidogrel responsiveness (P=0.051). We found no association between haemoglobin, blood glucose, HbA1c, cholesterol, liver enzymes, serum urea concentration or creatinine levels and clopidogrel resistance.Conclusion. Clopidogrel remains an effective treatment to prevent recurrent ischemic stroke in Indonesia. Further studies are needed to assess gene polymorphism and clopidogrel resistance, which may explain the findings of this study.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results